SG11201907701YA - Composition and method for preventing or delaying onset of myopia comprising atropine - Google Patents
Composition and method for preventing or delaying onset of myopia comprising atropineInfo
- Publication number
- SG11201907701YA SG11201907701YA SG11201907701YA SG11201907701YA SG11201907701YA SG 11201907701Y A SG11201907701Y A SG 11201907701YA SG 11201907701Y A SG11201907701Y A SG 11201907701YA SG 11201907701Y A SG11201907701Y A SG 11201907701YA SG 11201907701Y A SG11201907701Y A SG 11201907701YA
- Authority
- SG
- Singapore
- Prior art keywords
- singapore
- international
- myopia
- preventing
- pct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762461723P | 2017-02-21 | 2017-02-21 | |
PCT/IB2018/051039 WO2018154440A1 (en) | 2017-02-21 | 2018-02-20 | Composition and method for preventing or delaying onset of myopia comprising atropine |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201907701YA true SG11201907701YA (en) | 2019-09-27 |
Family
ID=63253608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201907701YA SG11201907701YA (en) | 2017-02-21 | 2018-02-20 | Composition and method for preventing or delaying onset of myopia comprising atropine |
Country Status (10)
Country | Link |
---|---|
US (1) | US11253507B2 (ko) |
EP (1) | EP3585386A4 (ko) |
JP (2) | JP2020509085A (ko) |
KR (1) | KR20200007769A (ko) |
CN (1) | CN110545813A (ko) |
AU (1) | AU2018224426B2 (ko) |
NZ (1) | NZ756936A (ko) |
PH (1) | PH12019501945A1 (ko) |
SG (1) | SG11201907701YA (ko) |
WO (1) | WO2018154440A1 (ko) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016172712A2 (en) | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
US11382909B2 (en) | 2014-09-05 | 2022-07-12 | Sydnexis, Inc. | Ophthalmic composition |
US11052094B2 (en) | 2015-05-29 | 2021-07-06 | Sydnexis, Inc. | D2O stabilized pharmaceutical formulations |
IL298796A (en) * | 2020-06-02 | 2023-02-01 | Univ Columbia | Methods and preparations for the prevention and treatment of myopia (myopia) with levocevastine, a selective antagonist of the H1-histamine receptor, and its derivatives |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8299062B2 (en) * | 2003-09-17 | 2012-10-30 | Franklin Volvovitz | Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction |
WO2012161655A1 (en) * | 2011-05-23 | 2012-11-29 | Singapore Health Services Pte Ltd | Composition and/or method for reducing and/or preventing myopia progression comprising atropine |
WO2016172712A2 (en) * | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
US9421199B2 (en) * | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
CN117205209A (zh) * | 2016-05-25 | 2023-12-12 | 新加坡保健服务集团 | 含有阿托品的水性组合物 |
-
2018
- 2018-02-20 AU AU2018224426A patent/AU2018224426B2/en active Active
- 2018-02-20 SG SG11201907701YA patent/SG11201907701YA/en unknown
- 2018-02-20 JP JP2019566000A patent/JP2020509085A/ja not_active Withdrawn
- 2018-02-20 KR KR1020197027649A patent/KR20200007769A/ko not_active IP Right Cessation
- 2018-02-20 NZ NZ756936A patent/NZ756936A/en unknown
- 2018-02-20 EP EP18756627.8A patent/EP3585386A4/en active Pending
- 2018-02-20 WO PCT/IB2018/051039 patent/WO2018154440A1/en unknown
- 2018-02-20 CN CN201880025791.XA patent/CN110545813A/zh active Pending
- 2018-02-20 US US16/487,423 patent/US11253507B2/en active Active
-
2019
- 2019-08-22 PH PH12019501945A patent/PH12019501945A1/en unknown
-
2021
- 2021-12-27 JP JP2021211859A patent/JP2022046673A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
PH12019501945A1 (en) | 2020-07-06 |
NZ756936A (en) | 2022-11-25 |
EP3585386A4 (en) | 2020-12-30 |
WO2018154440A1 (en) | 2018-08-30 |
EP3585386A1 (en) | 2020-01-01 |
AU2018224426A1 (en) | 2019-09-26 |
US20200138801A1 (en) | 2020-05-07 |
US11253507B2 (en) | 2022-02-22 |
AU2018224426B2 (en) | 2023-05-18 |
KR20200007769A (ko) | 2020-01-22 |
JP2022046673A (ja) | 2022-03-23 |
JP2020509085A (ja) | 2020-03-26 |
CN110545813A (zh) | 2019-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201907701YA (en) | Composition and method for preventing or delaying onset of myopia comprising atropine | |
SG11201908813QA (en) | Anti-sirp alpha antibodies | |
SG11201909963YA (en) | Methods for treating dravet syndrome | |
SG11201906431UA (en) | Method for the treatment of thromboembolism | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201804506RA (en) | Systems and methods for rendering multiple levels of detail | |
SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
SG11201805950UA (en) | Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them | |
SG11201901628XA (en) | Methods and compositions for spinal cord cells | |
SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201904535VA (en) | Prevention and treatment of bone and cartilage damage or disease | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
SG11201909602TA (en) | Compositions and methods involving probiotic molecules | |
SG11202000125TA (en) | Apparatus and methods for imaging | |
SG11201811329UA (en) | Spheroids including biologically-relevant materials and related methods | |
SG11201906616VA (en) | Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants | |
SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
SG11201811212SA (en) | Silane-mediated enhancement of rubber storage stability | |
SG11201910053YA (en) | Trisubstituted pyrimidine compounds and compositions for the treatment of cancer, retinal disorders, and cardiomyopathies |